Levemir

Levemir is a brand name of insulin detemir, approved by the FDA in the following formulation(s):

LEVEMIR (insulin detemir recombinant - injectable; subcutaneous)

• 
  Manufacturer: NOVO NORDISK INC
  
  Approval date: June 16, 2005
  
  Strength(s): 100 UNITS/ML ^[RLD]

Has a generic version of Levemir been approved?

No. There is currently no therapeutically equivalent version of Levemir available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Levemir. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Acylated insulin
  Patent 5,750,497
  Issued: May 12, 1998
  Inventor(s): Havelund; Svend & Halstr.o slashed.m; John & Jonassen; Ib & Andersen; Asser Sloth & Markussen; Jan
  Assignee(s): Novo Nordisk A/S
  The present invention relates to human insulin derivatives having a protracted profile of action in which the A21 and B3 amino acid residues are, independently, any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; Phe.sup.B1 may be deleted; the B30 amino acid residue is (a) a non-codable, lipophilic amino acid having from 10 to 24 carbon atoms in which case an acyl group of a carboxylic acid with up to 5 carbon atoms is bound to the E-amino group of Lys.sup.B29 ; (b) any amino acid residue which can be coded by the genetic code except Lys, Arg and Cys, in which case a lipophilic substituent is bound to the E-amino group of Lys.sup.B29 ; or (c) deleted, in which case a lipophilic substituent is bound to the E-amino group of LyS.sup.B29 ; and any Zn.sup.2+ complexes thereof; provided that when the B30 amino acid residue is Thr or Ala, the A21 and B3 amino acid residues are both Asn and Phe.sup.B1 is present, then the insulin derivative is a Zn.sup.2 + complex.
  
  Patent expiration dates:
  
  
  • May 16, 2019
    
    ✓ 
    Patent use: LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Insulin preparations containing NaCl
  Patent 5,866,538
  Issued: February 2, 1999
  Inventor(s): Norup; Elsebeth & Langkj.ae butted.r; Liselotte & Havelund; Svend
  Assignee(s): Novo Nordisk A/S
  Insulin preparations of superior chemical stability, comprising human insulin or an analogue or derivative thereof, glycerol and/or mannitol, and 5 to 100 mM of a halogenide are disclosed.
  
  Patent expiration dates:
  
  
  • June 20, 2017
    
    ✓ 
    Drug product
  
  



• 
  Acylated insulin
  Patent 6,011,007
  Issued: January 4, 2000
  Inventor(s): Havelund; Svend & Halstrom; John & Jonassen; Ib & Andersen; Asser Sloth & Markussen; Jan
  Assignee(s): Novo Nordisk A/S
  The present invention relates to protracted human insulin derivatives in which the A21 and the B3 amino acid residues are, independently, any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; Phe.sup.B1 may be deleted; the B30 amino acid residue is (a) a non-codable, lipophilic amino acid having from 10 to 24 carbon atoms, in which case an acyl group of a carboxylic acid with up to 5 carbon atoms is bound to the .epsilon.-amino group of Lys.sup.B29 ; or (b) the B30 amino acid residue is deleted or is any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys, in any of which cases the .epsilon.-amino group of Lys.sup.B29 has a lipophilic substituent; and any Zn.sup.2+ complexes thereof with the proviso that when B30 is Thr or Ala and A21 and B3 are both Asn, and Phe.sup.B1 is present, then the insulin derivative is always present as a Zn.sup.2+ complex.
  
  Patent expiration dates:
  
  
  • February 2, 2014
    
    ✓ 
    Patent use: LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Acylated insulin
  Patent 6,869,930
  Issued: March 22, 2005
  Inventor(s): Havelund; Svend & Halstrom; John & Jonassen; Ib & Andersen; Asser Sloth & Markussen; Jan
  Assignee(s): Novo Nordisk A/S
  The present invention relates to protracted human insulin derivatives in which the A21 and the B3 amino acid residues are, independently, any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; PheB1 may be deleted; the B30 amino acid residue is (a) a non-codable, lipophilic amino acid having from 10 to 24 carbon atoms, in which case an acyl group of a carboxylic acid with up to 5 carbon atoms is bound to the ε-amino group of LysB29; or (b) the B30 amino acid residue is deleted or is any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys, in any of which cases the ε-amino group of LysB29 has a lipophilic substituent; and any Zn2+ complexes thereof with the proviso that when B30 is Thr or Ala and A21 and B3 are both Asn, and PheB1 is present, then the insulin derivative is always present as a Zn2+ complex.
  
  Patent expiration dates:
  
  
  • February 2, 2014
    
    ✓ 
    Patent use: LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

See also...

• Levemir Consumer Information (Drugs.com)
• Levemir Cartridges Consumer Information (Wolters Kluwer)
• Levemir Vials Consumer Information (Wolters Kluwer)
• Levemir Consumer Information (Cerner Multum)
• Levemir FlexPen Consumer Information (Cerner Multum)
• Levemir Advanced Consumer Information (Micromedex)
• Levemir AHFS DI Monographs (ASHP)
• Insulin Detemir Cartridges Consumer Information (Wolters Kluwer)
• Insulin Detemir Vials Consumer Information (Wolters Kluwer)
• Insulin detemir Consumer Information (Cerner Multum)
• Insulin detemir Subcutaneous Advanced Consumer Information (Micromedex)
• Insulin Detemir AHFS DI Monographs (ASHP)